Novo Nordisk
VC Fund
Bagsværd, Denmark
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity.
- Total investments:
- 21
- Last investment:
- Lead investor:
- 48%
Last updated:
For AI agents: llms.txt
Industries Novo Nordisk invests in
Stages Novo Nordisk invests in
Countries Novo Nordisk invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 12 contacts → | |||
Round size
- Series A
- $5M–$17M
- Series C
- $16M–$57M
Investment Focus
Industry
- Biotechnology 13 (62%)
- Health Care 10 (48%)
- Therapeutics 6 (29%)
- Pharmaceutical 5 (24%)
- Medical 4 (19%)
Stage
- Corporate Round 4 (19%)
- Series A 3 (14%)
- Series C 3 (14%)
- Seed 2 (10%)
- Series B 2 (10%)
Country
- United States 9 (43%)
- Denmark 3 (14%)
- Canada 1 (5%)
- France 1 (5%)
- Belgium 1 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Adela Michea
Director of Portfolio, Communication & Organisational Readiness, Development External Innovation
|
Director of Portfolio, Communication & Organisational Readiness, Development External Innovation | Total investments: 1 | Find email | |
Christian Wenzel Tornøe
Principal Scientist
|
Principal Scientist | Total investments: 0 | Find email | |
|
Greg Jones
Vice President, Legal Affairs
|
Vice President, Legal Affairs | Total investments: 0 | Find email | |
Henrik Gürtler
Corporate Vice President of Human Resource Development
|
Corporate Vice President of Human Resource Development | Total investments: 0 | Find email | |
Jeppe Christiansen
Vice Chairman of the Board of Directors
|
Vice Chairman of the Board of Directors | Total investments: 3 | Find email | |
| See all 12 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Orbis Medicines is a novel macrocyclic chemistry and computational platform for high-throughput drug discovery. | Corporate Round / Sep 17, 2026 | ||
| Somite is a mission to transform the lives of millions of people by leveraging AI to produce human tissue for cell-based therapies. | Corporate Round / May 11, 2026 | ||
|
Proton HeartPet
|
Proton HeartPet is the company in the field of pet intelligent medical care. | Angel / Mar 23, 2026 | |
|
Cantoni Therapeutics
|
Grant / Sep 16, 2025 | ||
| Aspect Biosystems is a privately held biotechnology company combining the power of microfluidics and 3D bioprinting to fuel medical research and the development of bioprinted therapeutics. By adopting Aspect’s microfluidic 3D bioprinting platform and collaborating within Aspect’s network, researchers worldwide are accelerating the development andcommercialization of 3D bioprinted tissues. In addition, Aspect is advancing its internal regenerative medicine programs focused on metabolic diseases and musculoskeletal injuries and disorders and partnering with key industry players to bring bioprinted therapeutics to the clinic. | $115M / Series B / Jan 08, 2025 | ||
| Eikonizo is developing life-changing treatments by producing brain-penetrant small compounds and utilizing in vivo target engagement approaches to speed therapeutic discovery. | Corporate Round / Dec 10, 2024 | ||
|
Tanai Therapeutics
|
Tanai Therapeutics develops novel therapeutics for people living with obesity and obesity-related complications. | $3.5M / Seed / Sep 19, 2024 | |
| ElevateBio is an operator of a portfolio of cell and gene therapy companies intended to develop, manufacture, and commercialize life-transforming medicines.The company creates a portfolio through partnerships with the world's innovative scientists and inventors as well as it created a centralized facility that integrates all the elementsthat translate cell and gene therapy R&D into commercially viable therapies quickly and efficiently, enabling patients to get medical products to treat severe diseases.Vikas Sinha, Mitchell Finer, and David Hallal co-founded ElevateBio in Cambridge, Massachusetts in 2017. | $401M / Series D / May 24, 2023 | ||
| Aspect Biosystems is a privately held biotechnology company combining the power of microfluidics and 3D bioprinting to fuel medical research and the development of bioprinted therapeutics. By adopting Aspect’s microfluidic 3D bioprinting platform and collaborating within Aspect’s network, researchers worldwide are accelerating the development andcommercialization of 3D bioprinted tissues. In addition, Aspect is advancing its internal regenerative medicine programs focused on metabolic diseases and musculoskeletal injuries and disorders and partnering with key industry players to bring bioprinted therapeutics to the clinic. | Convertible Note / Apr 12, 2023 | ||
| The Sabi is a community-driven holistic beauty brand that empowers women from conception to postpartum, menopause, and everyday hormonal woes. | $163.8K / Pre-Seed / Apr 06, 2023 | ||
| See all 21 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Novo Nordisk invest in?
Novo Nordisk invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Corporate Round and Series A stage. Most of the 21 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Novo Nordisk's check size?
Novo Nordisk typically joins rounds of $5M–$17M at Series A and $16M–$57M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Novo Nordisk participates in.
How do I contact Novo Nordisk?
Public channels for Novo Nordisk include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Novo Nordisk?
The team at Novo Nordisk includes Adela Michea (Director of Portfolio, Communication & Organisational Readiness, Development External Innovation), Christian Wenzel Tornøe (Principal Scientist) and Greg Jones (Vice President, Legal Affairs), among 12 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
